Literature DB >> 18181034

Advances in the treatments of systemic vasculitides.

Loïc Guillevin1.   

Abstract

Necrotizing systemic vasculitides are severe diseases in which prognosis improved since steroids and cytotoxic agents have been prescribed. The outcome is now better, and remission is obtained in more than 80% of patients. In this review paper, we will cover the indications of conventional treatments and new biotherapies and other therapies. The strategies that improve patient's outcome are discussed in the light of the prospective trials organized by international research groups.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18181034     DOI： 10.1007/s12016-007-8068-4

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN： 1080-0549            Impact factor:   8.667


  58 in total

1.  Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report.

Authors:  Amy D Klion; Bruce S Bochner; Gerald J Gleich; Thomas B Nutman; Marc E Rothenberg; Hans-Uwe Simon; Michael E Wechsler; Peter F Weller
Journal:  J Allergy Clin Immunol       Date:  2006-05-03       Impact factor: 10.793

2.  The kidney in periarteritis nodosa.

Authors:  J DAVSON; J BALL; R PLATT
Journal:  Q J Med       Date:  1948-07

3.  Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity.

Authors:  D R Jayne; H Chapel; D Adu; S Misbah; D O'Donoghue; D Scott; C M Lockwood
Journal:  QJM       Date:  2000-07

4.  Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients.

Authors:  Loïc Guillevin; Alfred Mahr; Patrice Callard; Pascal Godmer; Christian Pagnoux; Emmanuelle Leray; Pascal Cohen
Journal:  Medicine (Baltimore)       Date:  2005-09       Impact factor: 1.889

5.  Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients.

Authors:  M Gayraud; L Guillevin; P le Toumelin; P Cohen; F Lhote; P Casassus; B Jarrousse
Journal:  Arthritis Rheum       Date:  2001-03

6.  Interferon-alpha treatment of four patients with the Churg-Strauss syndrome.

Authors:  E Tatsis; A Schnabel; W L Gross
Journal:  Ann Intern Med       Date:  1998-09-01       Impact factor: 25.391

7.  A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis.

Authors:  L Guillevin; J F Cordier; F Lhote; P Cohen; B Jarrousse; I Royer; P Lesavre; C Jacquot; P Bindi; P Bielefeld; J F Desson; F Détrée; A Dubois; E Hachulla; B Hoen; D Jacomy; C Seigneuric; D Lauque; M Stern; M Longy-Boursier
Journal:  Arthritis Rheum       Date:  1997-12

8.  Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Karina A Keogh; Mark E Wylam; John H Stone; Ulrich Specks
Journal:  Arthritis Rheum       Date:  2005-01

9.  Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients.

Authors:  Loïc Guillevin; Pascal Cohen; Alfred Mahr; Jean-Pierre Arène; Luc Mouthon; Xavier Puéchal; Edouard Pertuiset; Brigitte Gilson; Mohamed Hamidou; Patricia Lanoux; Alain Bruet; Marc Ruivard; Philippe Vanhille; Jean-François Cordier
Journal:  Arthritis Rheum       Date:  2003-02-15

10.  Hepatitis C virus infection in patients with essential mixed cryoglobulinemia.

Authors:  R Misiani; P Bellavita; D Fenili; G Borelli; D Marchesi; M Massazza; G Vendramin; B Comotti; E Tanzi; G Scudeller
Journal:  Ann Intern Med       Date:  1992-10-01       Impact factor: 25.391
View more
  1 in total

1.  Clinical features and prognostic factors of Churg-Strauss syndrome.

Authors:  Mi-Yeong Kim; Kyoung-Hee Sohn; Woo-Jung Song; Heung-Woo Park; Sang-Heon Cho; Kyung-Up Min; Hye-Ryun Kang
Journal:  Korean J Intern Med       Date:  2014-01-02       Impact factor: 2.884
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.